InterMune Gearing Up For Another Round With The FDA

Long Investing Ideas from Seeking Alpha

Thu, 29 Nov 2012

By Brian L. Wilson : After spending the last few months in a well-defined trading range of $8-10 per share, the pulmonary fibrosis drug development company InterMune (NASDAQ: ITMN ) has settled right in the middle (at $9/share) as investors wait for more news on its flagship product, pirfenidone. ...

Read the rest of this article on Long Investing Ideas from Seeking Alpha

Related Topics:

Content Partners

Site Directory Site Map Our Products

Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News

International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland

Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.